Stryker price target raised to $400 from $386 at RBC Capital

RBC Capital raised the firm’s price target on Stryker (SYK) to $400 from $386 and keeps an Outperform rating on the shares. The company’s “solid” Q3 results delivered a positive 2% sales surprise led by MedSurg, and its Q4 guide is seen as “conservative”, with Stryker’s “robust” business momentum continuing into 2025, the analyst tells investors in a research note.